Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Nanoparticle formulation‑specific testing is a dedicated service for drug product release of nanomedicines, including polymer nanoparticles, inorganic nanoparticles, micelles, and nanocrystals. It systematically characterizes particle size distribution and drug loading, with methods designed to align with ICH Q6B principles and FDA guidance on nanomaterials.
Nanomedicines improve solubility, stability, bioavailability, and targeting. Their physicochemical properties directly affect in vivo behavior, efficacy, and safety. The FDA 2022 guidance Drug Products, Including Biological Products, that Contain Nanomaterials requires characterization, control, testing, and confirmation of nanomaterial components, with emphasis on particle size distribution and its correlation with clinical outcomes.
While ICH Q6B primarily targets proteins and peptides, its quality by design (QbD) framework is widely adopted for nanomedicines. A 2023 study in APS PharmSci demonstrated orthogonal use of DLS and NTA to characterize oligonucleotide‑loaded LNPs, showing that orthogonal techniques can detect subpopulations missed by DLS alone.
| Test Category | Platform | Target | Regulatory Basis |
| Particle size distribution | DLS; NTA | Z‑average, PDI, distribution curve, subpopulation identification | FDA Nanomaterial Guidance; ICH Q6B |
| Drug loading | HPLC (optional LC‑MS/UV‑Vis) | Drug content, loading efficiency (%) | ICH Q6B; industry practice |
DLS is non‑invasive and highly sensitive. Laser light scattering from nanoparticles undergoing Brownian motion is detected, and the autocorrelation function is used to calculate the hydrodynamic diameter via the Stokes‑Einstein equation. Outputs include Z‑average (mean size) and polydispersity index (PDI). The typical size range for injectable nanocarriers is 10–500 nm.
NTA tracks individual nanoparticle Brownian motion in real time using scattered light or fluorescence. Unlike DLS, NTA provides particle‑resolved size distributions and can identify multiple subpopulations, making it valuable for polydisperse systems.
| Aspect | DLS | NTA |
| Principle | Ensemble average of intensity fluctuations | Single particle tracking |
| Accuracy | Good for monodisperse; poor for polydisperse | Good for both |
| Resolution | Low (requires >3× diameter difference) | High (resolves <0.5× difference) |
| Size range | 1–1000 nm | 30–1000 nm |
| Concentration range | 10⁸–10¹² particles/mL | 10⁷–10⁹ particles/mL |
| Output | Intensity distribution, Z‑average, PDI | Number distribution, particle concentration |
| Subpopulation detection | Limited | Strong (detects DLS‑invisible subpopulations) |
| Visualization | No | Yes |
| Standard | ISO 22412:2017 | ISO 19430:2016 |
Drug loading is defined as the mass of drug per total nanoparticle mass (%). It directly affects dosing and efficacy and must be controlled as a critical quality attribute. HPLC is used to quantify drug content after nanoparticle disruption. UV‑Vis may be used for nanoparticles with characteristic absorbance.
| Document | Section | Key Requirement |
| FDA Nanomaterial Guidance (2022) | Drug Products Containing Nanomaterials | Characterization, control, testing, and confirmation of nanomaterials; particle size distribution affects product characteristics and must be linked to clinical outcomes. |
| ICH Q6B | Specifications | QbD framework adopted for nanomedicine quality research. |
| ISO 22412:2017 | Particle size analysis – DLS | International standard for DLS. |
| ISO 19430:2016 | Particle size analysis – NTA | International standard for NTA. |
| USP <1058> | Analytical Instrument Qualification | AIQ requirements. |
For a customized testing strategy, method validation, or IND/BLA submission support for your nanoparticle formulation, contact Creative Biogene's technical team.
Q1: Are particle size, PDI, and drug loading all mandatory for nanomedicine release?
Yes. Particle size and PDI are critical quality attributes affecting in vivo behavior and stability. Drug loading directly impacts dosing and efficacy. The FDA Nanomaterial Guidance requires linking size distribution to clinical outcomes, and under ICH Q6B, all three are mandatory for release.
Q2: How do I choose between DLS and NTA for particle size testing?
Choose based on sample characteristics and purpose. DLS is the gold standard for routine release – fast (1‑3 min), high throughput, easy to use, suitable for monodisperse samples. NTA is orthogonal, provides true size distributions for polydisperse samples, and detects subpopulations missed by DLS. Our recommendation: DLS for routine release; DLS + NTA dual platform for development and polydisperse system validation.
Q3: What is the difference between drug loading and encapsulation efficiency?
Drug loading is the mass of drug per total nanoparticle mass (mg drug/g NP or %), reflecting how much drug is delivered per unit carrier – key for dosing. Encapsulation efficiency is the percentage of total drug added that becomes encapsulated, reflecting process efficiency. Both are critical quality attributes. See our liposomal formulation testing page for encapsulation efficiency methods.
Q4: What are the key validation parameters for DLS?
Per ISO 22412:2017, core parameters are repeatability, intermediate precision, and reproducibility. Prepare five samples, measure each five times. Repeatability assesses multiple measurements on the same sample. Reproducibility involves a second analyst, second instrument, or both. Accuracy is verified using reference standards. Linearity, range, LOD, and LOQ are not applicable to DLS. For intensity‑average size, repeatability of ±20% is achievable; for PDI or distribution width, ±30%. For very small particles (e.g., 10 nm), ±20% may be challenging and should be justified.
Copyright © 2026 Creative Biogene. All rights reserved.